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Purpose: The aim of this study was to assess the effects of corneal 
collagen cross-linking (CXL) on uncorrected visual acuity (UCVA), 
best corrected visual acuity (BCVA), subjective refraction, corneal 
irregularity, anterior chamber depth (ACD), corneal thickness, and 
k-readings.
Patients and Methods: Eighty-four eyes of 44 patients with keratoconus 
were treated using corneal collagen cross-linking. UCVA, BCVA, and 
subjective refraction were evaluated pre-operatively as well as 3 months 
and 4 years after treatment and corneal Orbscan results were evaluated 
preoperatively and 4 years after treatment. Comparisons were made 
using paired sample t tests and a P values less than 0.05 were considered 
statistically significant.
Results: There was a significant reduction in the mean
thickness of the thinnest point of the cornea from 462.24 ± 46.95 µm
preoperatively to 454.36 ± 55.32 µm (P < 0.05) at the last follow-up. 
The mean maximum and mean minimum curvature values reduced 
significantly from 48.00 ± 4.02 D and 45.03 ± 2.88 D preopera-
tively to 47.56 ± 3.75 D (P < 0.05) and 44.64 ± 2.94 D (P < 0.001),
respectively at the last follow-up. The UCVA (P = 0.309), BCVA 
(P = 0.594), subjective spherical equivalent (P = 0.591), subjective
cylindrical refraction (P = 0.522), irregularity at the 3 mm
(P = 0.338) and 5 mm (P = 0.915) zone of the cornea, anterior
chamber depth (P = 0.072), and central corneal thickness (P = 0.203) 
remained unchanged. There were no significant postoperative
complications.
Conclusion: Based on our results, treatment of progressive
keratoconus with CXL can effectively stabilize UCVA, BCVA,
subjective spherical equivalent, subjective cylindrical refraction, 
corneal irregularity, central corneal thickness and anterior chamber 
depth while reducing keratometry readings. 
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Introduction
Keratoconus is a noninflammatory cone like 
ectasia of the cornea, which is usually bilat-
eral and progresses over time 1. Visual impair-
ment typically commences during adolescence 
and progresses thereafter 2. Further increase in 
myopia, irregular astigmatism, and subepithelial 
scarring results in visual impairment 3. Corneal
collagen cross-linking (CXL) using UVA and 
riboflavin was introduced by Wollensak et 
al., 4 as a method of halting the progression of
keratoconus. This therapy aims to increase cor-
neal biomechanical stability by inducing addi-
tional covalent binding between molecules of 
collagen. In vitro studies have shown increased 
corneal rigidity and increased corneal resis-
tance to enzymatic degradation after CXL 5-8. 
In this procedure, the cornea is saturated with
iso-osmolar riboflavin solution for 30 min
followed by 3 mW/cm2 UVA for 30 minutes. The 
treatment span is 1 h and the cumulative UVA dose 
is 5.4 J/cm2. Clinical studies have reported the ef-
ficacy and safety of this new treatment modality 
in reducing the progression of ectasia in keratoco-
nus patients 9-14. In the present study, the outcomes 
of CXL in patients with keratoconus is presented.
Patients and Methods
This study was conducted in accordance with 
the principles of the Declaration of Helsinki.
Prior to their participation, informed consent was
obtained from all study participants. Eighty-four 
eyes of 44 patients (30 male and 54 female) 
with keratoconus were enrolled in this study. 
The mean age was 27.13 ± 6.28 (range,14-43).
Patients who had severe central corneal scars 
and opacities; a history of herpetic keratitis, 
concurrent corneal infections, concomitant 
autoimmune diseases, or any ocular surgery; 
lens or retina abnormalities; and non- cooper-
ative patients were excluded. All procedures 
were performed in our institute by the same 
surgeon under sterile conditions. After topical 
anesthesia and inserting a wire lid speculum, 
the photosensitizing solution (0.1 % riboflavin 
in 20 % dextran) was instilled every 3 min for 
30 min. The penetration of riboflavin into the 
anterior chamber and corneal stroma was con-
firmed by slit lamp examination. The cornea 
was then irradiated with UVA for 30 min (radi-
ance of 3 mW/cm2) using a 370 nm UVA dou-
ble diode light source. During irradiation, the 
riboflavin solution was applied every 5 min-
utes. Balanced salts solution was frequently
applied intraoperatively to prevent dehydra-
tion. The patients were prescribed topical
antibiotics for 5 days along with tear substitutes 
for 3-4 weeks. Preoperative and postoperative
evaluation after 3 months and then 4 years
consisted of uncorrected visual acuity 
(UCVA), best corrected visual acuity (BCVA),
subjective refraction, slit lamp, and fundus
examinations. Corneal topography (Orbscan 
IIz; Bausch & Lomb, Rochester, NY) was
performed preoperativly and then 4 years after 
CXL Statistical evaluation of values before as 
well as 3 months and 4 years after CXL was 
performed using SPSS software version 20 
(Armonk, NY: IBM Corp). The normality of 
the data was tested using the Kolmogorov–
Smirnov test. Depending on the data distribu-
tion, paired t tests or Wilcoxon’s paired test 
was used to check the differences. The level 
of statistical significance was set at P < 0.05.
The study was approved by the ethics
committee of the Basir Eye Health Research 
Center, Tehran, Iran.
Results
Visual Acuity and Refraction Results
The preoperative and postoperative data are
presented in table 1. No statistically significant
differences were observed in UCVA or BCVA 
at 3 months and 4 years post treatment
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compared to the preoperative values (UCVA; 
P = 0.371, P = 0.309, BCVA; P = 0.136,
P = 0.594,  respectively). Similarly, the change in
spherical equivalent and cylindrical refraction 
was not significant at 3 months and 4 years
after CXL (subjective SE; P = 0.279, P = 0.591,
subjective CYL; P = 0.423, P = 0.522, respectively).
Topographic Results
There was a significant decrease in the 
mean thickness of the thinnest point of the
cornea from 462.24 ± 46.95 µm preoperative-
ly to 454.36 ± 55.32 µm (P < 0.05) at the last
follow-up. The mean maximum and mean
minimum curvature values decreased signifi-
cantly from 48.00 ± 4.02 D and 45.03 ± 2.88 
D preoperatively to 47.56 ± 3.75 D (P < 0.05) 
and 44.64 ± 2.94 D (P < 0.001), respectively 
at the last follow-up. Figure 1 shows changes 
of K-readings after corneal CXL. No statisti-
cally significant difference was detected in the 
central corneal thickness (P = 0.203), anterior
chamber depth (P = 0.072), irregularity at the 3mm
(P = 0.338) and 5mm (P = 0.915) zones of the 
cornea, at the last follow-up compared to the
preoperative values. Figure 2 shows changes of 
corneal thickness.
Table 1: Patients’ visual acuity before and after treatment 
Parameters
(mean ± SD)















3.08 - 4.11 ± 3.96
P = 0.279
- 3.69 ± 3.15
P = 0.591
SUB AST - 2.37 ± 1.49 - 2.66 ± 1.54
P = 0.423
- 2.34 ± 1.49
P = 0.522
 Figure1: Change in K-readings (D) after CXL
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Figure 2: Change in corneal thickness (μm) after CXL
Discussion
Corneal CXL is a minimally invasive and
relatively inexpensive treatment protocol that 
can halt keratoconus with high success rates even 
over the long-term. It flattens the cornea and in 
some cases, increases the visual acuity 15. This 
study investigated the effect of CXL on UCVA, 
BCVA, and topographical values. After 4 years 
of follow-up, the study demonstrated that treat-
ing cases of progressive keratoconus with CXL 
can stabilize UCVA, BCVA, subjective spheri-
cal equivalent, subjective cylindrical refraction, 
central corneal thickness, anterior chamber 
depth and irregularity at the 3 mm and 5mm 
zones of the cornea in the long term. The ob-
served changes after CXL included reduced 
thinnest point of the cornea, as well as a signif-
icant decrease in maximum and minimum 
curvature values.
Visual Acuity and Refraction Results
Changes in visual outcome were carefully doc-
umented over time because a comprehensive 
understanding of visual responses in postoper-
ative time course will greatly help physicians 
in setting realistic patient expectations after 
CXL. In this study, UCVA and BCVA showed 
no change. Our results show that 75 % of
patients had improved or unchanged UCVA, 
70.23 % had Improved or unchanged BCVA, 
whereas 25 % lost lines of UCVA and 29.77 % 
lost lines of BCVA at the last follow-up. Oth-
er short and long-term studies have reported
significant continuous improvement in visual
Caporossi et al., 16 have reported Significant 
improvement in both UCVA and BCVA after 6 
months, 16 1 year, 17 and 2 years, 18 of follow up 
has been previously reported. Also after 1 year 
of follow-up, Grewal et al., 19 reported stable 
BCVA. 
Topographic Results
The present study demonstrated a decrease 
of 0.44 ± 1.39 D in max-K and 0.39 ± 0.88 
D in min-K at the last follow-up 4 years
after CXL. This is similar to previous published 
results. Wollensak et al., 20 reported a decrease 
in the maximum keratometry readings by 2.01 
D. Derakhshan et al., 21 demonstrated that the 
maximum and mean K values decreased by 
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0.65 D and 0.51 D respectively. Raiskup-Wolf 
et al., 22 reported reduced curvature of 2.68 D 
in the first year, 2.21 D in the second year, and 
4.84 D in the third year.
In the current study, changes in corneal thickness 
were evaluated after the CXL treatment. There 
was a significant reduction in the mean thickness 
of the thinnest point of cornea and no statistically 
significant difference was detected in the central 
corneal thickness. Thus far, the effect of CXL on 
corneal thickness has been less clear. Thinning 
immediately after CXL has been reported and 
is thought to be the result of several factors, 
including treatment-related effects from stromal 
compaction, postoperative dehydration, and
alterations in epithelial healing and dis-
tribution 23,24. It also may represent a mea-
surement artefact after treatment 25. Lon-
ger-term observations vary from no change 
in corneal thickness 16 to a decrease at 12 
months 18 and an increase at 24 months 22. 
The present study showed no statistically sig-
nificant difference in anterior chamber depth at 
the last follow-up compared to the preoperative 
values. Polat et al., 26 reported that the preoper-
ative ACD values were significantly lower than 
the postoperative values. Emre et al.,27 studied 
216 previously untreated keratoconus patients 
and found that the ACD showed a significant 
increase with increasing keratoconus stage, and 
that this increase could be as a result of ante-
rior protrusion of the cornea. They found that 
the ACA showed a significant decrease and 
stated that this could be due to the compensa-
tory flattening of the peripheral cornea. Abol-
bashari et al., 28 reported a correlation between
corneal curvatures and anterior segment
parameters in keratoconus patients with pe-
ripheral ACD, usually being related to the anterior
corneal curvature. Toprak and Yildirim 29
evaluated 47 keratoconic eyes during a 6-month
period following CXL. They reported no 
significant change in ACD values. Anoth-
er study conducted by De Bernardo et al., 11
reported that there was no change in ACD
values. They argued that the stability of the 
ACD was associated with the increase in
axial length (AL). New studies measuring 
the pre and post-CXL iris–lens diaphragm
positions and changes can better  clarify this 
subject. 
Conclusion
Based on our results, treatment of progressive 
keratoconus with CXL can effectively stabilize 
UCVA, BCVA, subjective spherical equiva-
lent, subjective cylindrical refraction, corneal
irregularity, central corneal thickness and
anterior chamber depth while reducing
keratometry readings. 
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